share_log

JP Morgan Downgrades Emergent BioSolutions to Underweight, Lowers Price Target to $9

Benzinga ·  Mar 17, 2023 19:44

JP Morgan analyst Jessica Fye downgrades Emergent BioSolutions (NYSE:EBS) from Neutral to Underweight and lowers the price target from $23 to $9.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment